COMPOSITION CONTAINING LUTEIN/LUTEIN ESTER AND APPLICATIONS THEREOF

Abstract

Disclosed in the present invention are a composition containing lutein/lutein ester and applications thereof. Components of the composition containing lutein/lutein ester comprise lutein/lutein ester, -carotene and a pharmaceutically acceptable carrier. The weight ratio of lutein/lutein ester to -carotene is 1:0.1-100. In the present invention, by cooperatively using lutein/lutein ester and -carotene and using auxiliary natural healthy ingredients, the dosage form of an orally disintegrating tablet is prepared. The orally disintegrating tablet is absorbed through the oral cavity, has fast effectiveness and small first-pass effect, reduces damage of gastric acid to lutein/lutein ester, has high bioavailability, and has the characteristics of nutritional and health-care effects, good mouthfeel and fast absorption. By eating the product, visual power can be obviously enhanced, the ocular blood flow is increased, and eye muscle fatigue is alleviated, and accordingly the morbidities of cataract, senile niacula lutea retinae lesion and adolescent myopia are reduced.

Claims

1-7. (canceled)

8. A composition containing lutein/lutein ester, wherein the composition comprises lutein/lutein ester and beta-carotene and pharmaceutically acceptable carriers, the weight ratio of lutein/lutein ester to beta-carotene is 1.5-10:1, the composition comprises the following components by weight: TABLE-US-00011 lutein/lutein ester 0.5-25%.sup. cyclodextrin 4.5-45%.sup. acidity regulator 3-10% loose agent 3-15% calcium carbonate 0-5% lactose 10-25% maltodextrin 5-25% alditol 5-20% beta-carotene 0.1-25%.sup. sugar powder 5-30% fruit powder 12-30% magnesium stearate 0.5-1.5%,.sup. and the composition is orally disintegrating tablet.

9. The composition containing lutein/lutein ester according to claim 8, wherein the composition comprises the following components by weight: TABLE-US-00012 lutein/lutein ester 1.5-2% cyclodextrin 9-10% acidity regulator 5-6% loose agent 7-8% calcium carbonate 0-1% lactose 13-15% maltodextrin 12-15% alditol 10-14% beta-carotene 1-2% sugar powder 14-15% fruit powder 17-22% magnesium stearate 1-1.5%.

10. The composition containing lutein/lutein ester according to claim 8, wherein the acidity regulator is one or more selected from the group consisting of citric acid, malic acid, fumaric acid, lactic acid and tartaric acid; the loose agent is one or more selected from the group consisting of soda, baking soda, calcium carbonate and magnesium carbonate; the sugar powder is one or more selected from the group consisting of white granulated sugar powder, fructose powder and glucose powder; the fruit powder is one or more of the darker fruit powders selected from the group consisting of blueberry powder, black currant powder, cranberry powder, tomato powder, grape powder and mulberry powder; the alditol is one or more selected from the group consisting of sorbitol, mannitol, xylitol, and erythritol.

11. A method for treating ocular diseases or for providing ocular health care, comprising administering to a subject in need thereof an effective amount of the composition according to claim 8.

12. The method according to claim 11, wherein the ocular diseases comprise dizziness, eye pain, weak dark adaptation, blurred vision, photophobia, dry eyes, blink, myopia or macular degeneration of retina.

Description

DETAILED DESCRIPTION

Example 1

[0024] Formulation: (by Weight)

TABLE-US-00003 lutein ester 2% cyclodextrin 9% citric acid 6% calcium carbonate 1% lactose 15% maltodextrin 12% xylitol 14% beta-carotene 2% fructose powder 14% cranberry fruit powder 17% magnesium stearate 1% sodium bicarbonate 7%

[0025] Preparation Process:

[0026] Each of the components is mixed and then prepared into an orally disintegrating tablet by the method known in the art. Clinical Observation:

[0027] (1) Clinical Data

[0028] Clinical trials were performed on 220 outpatients who were not hospitalized and volunteered to participate in the trial with clinical manifestations of dizziness, eye pain, weak dark adaptation, blurred vision, photophobia, dry eyes, blink; wherein 110 patients were arranged in the treatment group (male:female=1:1), and 110 patients were arranged in the control group (male:female=1:1).

[0029] (2) Treatment

[0030] Zhen Shi Ming eye drops were applied to the control group with once a day and 15 days for a course of treatment; the preparation of the present invention was administrated orally to the treatment group with 550 mg/tablet and 4 tablets a day.

[0031] (3) The clinical trial results are recorded as follows:

TABLE-US-00004 Control group Treatment group Effective Effective number number Before after Effective Before after Effective Symptom administration administration rate % administration administration rate % Dizziness 15 6 40 18 15 83 Eye pain 17 6 35 14 12 86 Weak dark 12 4 33 14 13 93 adaptation Blurred vision 20 9 45 21 18 86 Photophobia 15 8 53 12 10 83 Dry eyes 16 8 50 16 14 88 Blink 15 8 53 15 12 80

[0032] There is a significant difference between the treatment group and the control group. Therefore, the preparation of the present invention has significant efficacy on clinical application.

Example 2

[0033]

TABLE-US-00005 lutein 1.5% cyclodextrin 10% citric acid 4% malic acid 1% sodium carbonate 1.5% sodium bicarbonate 6.5% lactose 13.0%.sup. maltodextrin 15% erythritol 10% beta-carotene 1% fructose powder 15% blueberry powder 15% black currant powder 5% magnesium stearate 1.5%

[0034] Clinical Observation:

[0035] (1) Clinical Data

[0036] Clinical trials were performed on 180 outpatients who were not hospitalized and volunteered to participate in the trial with clinical manifestations of dizziness, eye pain, weak dark adaptation, blurred vision, photophobia, dry eyes, blink; wherein 100 patients were arranged in the treatment group (male:female=1:1), and 80 patients were arranged in the control group (male:female=1:1).

[0037] (2) Treatment

[0038] Eye drops were applied to the control group with once a day and 15 days for a course of treatment; the preparation of the present invention was administrated orally to the treatment group with 550 mg/tablet and 4 tablets a day.

[0039] (3) The clinical trial results are recorded as follows:

TABLE-US-00006 Control group Treatment group Effective Effective number number Before after Effective Before after Effective Symptom administration administration rate % administration administration rate % Dizziness 12 6 50 15 13 87 Eye pain 12 6 50 14 12 86 Weak dark 10 4 40 13 11 85 adaptation Blurred vision 11 6 55 18 17 94 Photophobia 15 7 47 12 10 83 Dry eyes 10 5 50 15 14 93 Blink 10 4 40 13 11 85

[0040] There is a significant difference between the treatment group and the control group. Therefore, the preparation of the present invention has significant efficacy on clinical application.

[0041] Stability Test

TABLE-US-00007 Absorbance values at different time period Sample Conditions 0 h 1 h 6 h 24 h 72 h 240 h Example 1 Illumination 0.853 0.104 Double 0.853 0 849 0.850 0.847 0 853 0.855 aluminum package Example 2 Illumination 0.855 0.003 Double 0.855 0.855 0.852 0.850 0.843 0.845 aluminum package

[0042] Illumination has a strong destructive effect on the stability of the product, and the product with double aluminum package has good stability.

[0043] Effect of pH on the Stability of Lutein/Lutein Ester

[0044] The acetone aqueous solutions of lutein and lutein ester with pH 1.5 and pH 3 were prepared respectively, and the absorbance values at different time period are shown as follows:

TABLE-US-00008 Absorbance values at different time period Sample Conditions 0 h 12 h 24 h 36 h 48 h 96 h Lutein pH 1.5 0.843 0.559 0.452 0.368 0.267 0.151 pH 3.0 0.845 0.566 0.495 0.428 0.341 0.268 Lutein pH 1.5 0.844 0.588 0.466 0.377 0.259 0.155 ester pH 3.0 0.837 0.597 0.502 0.439 0.356 0.274

[0045] The above data shows that absorbance values of lutein ester and lutein decrease significantly under strong acid conditions. The retention of lutein ester is 18.36% and of lutein is 17.80% after placing for 96 h at pH 1.5.

[0046] Animal Experiment

[0047] 1. Purpose of the Test

[0048] Comparison and evaluation of pharmacokinetic properties of rats after oral and intragastric administration of the preparation of the examples under fasting conditions

[0049] 2. Test Method

[0050] 2.1 Test Drugs

[0051] Preparation for the Test: Example 2;

[0052] Dosage for the administration of the preparation: Lutein concentration 10 mg/kg

[0053] 2.2 Test Animals

[0054] Male SD rats, 7-8 weeks old, weighing 180-220 g, were provided by the Animal Testing Center of Shanghai Institute of Materia Medica with the license number SYXK (Hu)2010-0049. Adaptive feeding was performed on the tested animals at the test site for 3-7 days before the test day.

[0055] 2.3 Test Design

[0056] 16 SD rats, male, were randomly divided into 4 groups, with 4 in each group. Each of the preparations was administrated orally and intragastricly respectively, and the specific arrangement is shown in Table 1 below:

TABLE-US-00009 TABLE 1 Test group table Dosage of the Number Adminis- adminis- Manner of of the trated tration Fasting adminis- Group animal preparation (mg/kg) or not tration 1 4 Test 10 Fasting Oral preparation 2 4 Test 10 Fasting Intragastric preparation

[0057] Fasting was performed for 12 h before administration with free drinking of water. Food was provided uniformly at 2 h after administration.

[0058] 2.4 Time Point for Blood Collection and Sample Processing:

[0059] 0.25, 0.5, 1.0, 2.0, 3.0, 5.0, 7.0, 10 and 24 h after administration;

[0060] At the above set time points, 0.2 ml of venous blood was taken from the posterior venous plexus of the rat eyeball, and placed in a heparinized tube. Centrifugation was performed at 11,000 rpm for 5 min to separate the plasma. Freezing was conducted in a refrigerator at 20 C.

[0061] 2.5 Sample Detection

[0062] The concentration of lutein in plasma was determined by LC-MS/MS, the linear range in the analytical method was 3.00300 ng/mL.

[0063] 3 Test Results

[0064] For the rats administrated intragastricly 10 mg/kg of the test preparation, lutein was not detected in plasma (the content of lutein was reduced by gastric acid, and was below the minimum detectable concentration limit).

[0065] For the rats administrated orally 10 mg/kg of the test preparation, the concentration of lutein in plasma is shown in Table 2.

TABLE-US-00010 TABLE 2 Plasma concentration of lutein after oral administration of 10 mg/kg of test preparation 1 in rats (ng/mL) Time/h 1 2 3 4 Average Standard deviation 0.25 3.96 BLQ BLQ BLQ 0.99 1.98 0.5 3.33 13.2 3.22 4.36 6.03 4.81 1 15.8 46.4 5.78 15.7 20.9 17.6 2 12.3 52.2 8.66 12.5 21.4 20.6 3 9.13 38.3 8.33 6.81 15.6 15.1 5 6.82 13.8 7.04 10.5 9.54 3.30 7 6.25 23.4 8.39 9.69 11.9 7.8 10 4.90 7.29 BLQ 5.51 4.43 3.12 24 BLQ 3.98 BLQ BLQ 1.00 1.99

[0066] As can be known from the results that, gastric acid has a certain destructive effect on the stability of lutein/lutein ester and reduces its bioavailability. Increase of the absorption of lutein/lutein ester by oral mucosa is an effective way to improve its bioavailability.